Exxon Mobil was upgraded by Bank of America Merrill Lynch and the raised price target caused stocks to get a lift in the morning session. However, the boost did not last long and stocks began to give back those gains. Ben Willis of Albert Fried notes many stocks being sold are ones with high margin requirements. Willis mostly sees a sector rotation happening out of the names and going into lower beta names. He also points out the biotech weakness at NASDAQ.
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.